Adding finerenone to SGLT2 inhibitors and long-term kidney outcomes in diabetic kidney disease
Matsui M, Nishimoto M, Kosugi T, et al.
Diabetes Obes Metab. Pub. online 31 May 2026.
Leggi
Impact of sleeve gastrectomy versus intensive lifestyle modifications with obesity management medications on BMI trajectory and target attainment: a prospective matched cohort study
Russo MF, Casella G, Angelini G, et al.
Diabetes Obes Metab. Pub. online 31 May 2026.
Leggi
Efficacy and safety of once-weekly and once-daily basal insulins in type 1 diabetes mellitus: a systematic review and network meta-analysis of clinical trials
Amaral R, Costa B, Penedones A, et al.
Diabetes Obes Metab. Pub. online 1 Jun 2026.
Leggi
Oral semaglutide 25 mg versus orforglipron 36 mg in obesity: a population-adjusted indirect treatment comparison
Michalak W, Bøg M, Bendixen T, et al.
Diabetes Obes Metab. Pub. online 1 Jun 2026.
Leggi
In ricordo di Carlo Petrini
Carlo "Carlin" Petrini ci ha lasciati. Con lui se ne va una delle voci più originali e coraggiose del nostro tempo, e un amico prezioso per AMD. Fondatore di Slow Food, ideatore di Terra Madre e dell'Università di Scienze Gastronomiche di Pollenzo, Petrini ha cambiato il modo in cui il…
Leggi
Beyond weight loss: multisystem benefits of obesity medications
Savas M, Kuckuck S, Boon MR, van Rossum EFC
Lancet Diabetes Endocrinol. Pub. online 28 May 2026.
Leggi
Kidney and survival benefits of semaglutide in diabetes with chronic kidney disease: FLOW trial cardiovascular subgroup analyses
Tuttle K, Bakris G, Baeres F, et al.
J Am Coll Cardiol. Pub. online 2 Jun 2026.
Leggi
Comparative effects of individual glucagon-like peptide-1 receptor agonist-based medications on direct measurement of body composition among adults with overweight or obesity with or without type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Wachiraphansakul N, Vongchaiudomchoke T, Manosroi W, et al.
Diabetes Obes Metab. Pub. online 28 May 2026.
Leggi
GIP in cardiovascular and kidney disease: from physiology to pharmacology
De Fano M, Haurum LL, Schwarz CR, et al.
Diabetes Obes Metab. Pub. online 28 May 2026.
Leggi
A phase 2 trial of frexalimab, a cd40l antagonist, in adolescents and adults with recent‐onset type 1 diabetes (FABULINUS): rationale and study design
Cherkas A, Rotthaeuser B, Porksen N, et al.
Diabetes Obes Metab. Pub. online 27 May 2026.
Leggi